• Provide evidence-based recommendations on drug development strategy for biotech and pharma clients; incorporating scientific, clinical, commercial, and regulatory insights.• Conduct opportunity assessments for early-stage assets and inform market positioning strategies that mitigate development risk and maximize valuation.• Perform in-depth competitive landscape assessments and predict future trends.• Prioritize indications and therapeutic targets for new development programs or label expansions.• Generate revenue forecasts to support portfolio valuation and commercial decisions.• Responsible for managing teams of 3-5 on the execution and delivery of projects.• Areas of expertise: oncology, autoimmune, neurological diseases, adoptive cell therapies, etc.

• Engaged with economic development team to facilitate academic and industry partnerships that stimulate growth of high-tech jobs in the Buffalo-Niagara region.• Evaluated the University's strategic position to support early-stage drug development and GMP biomanufacturing, considering commercial trends, internal capabilities, and cost-benefit outcomes.• Conducted primary and secondary research to develop value propositions for a diverse portfolio of academic technologies, ranging from regenerative medicine to machine learning.

• Led collaborations between the University at Buffalo and the University of Pennsylvania in research projects deploying a leading proteomics platform to characterize genes in bone development and skeletal aging.• Established a novel mechanism of Rgs12 in promoting intracellular reactive oxygen species and enhancing the formation of osteoclasts, the cells responsible for bone resorption.• Applied statistical and data mining techniques to interpret data from large-scale "omics" datasets, discovering major discrepancies between two important osteoclast cell models used for 20+ years.• Mentored and led a team of undergraduate researchers in a recombinant protein engineering project.

(Previously Kinex Pharmaceuticals)• Collaborated with the R&D team to screen small-molecule drug candidates for a novel class of immunosuppressants.• Established the mechanism-of-action for T cell function inhibitors in the calcium-dependent T cell activation pathway.